BGM Durie1, J-L Harousseau2, JS Miguel3, J Blade.4, B Barlogie5, K Anderson6, M Gertz7,
M Dimopoulos8, J Westin9, P Sonneveld10, H Ludwig11, G Gahrton12, M Beksac13, J Crowley14,
A Belch15, M Boccadaro16, I Turesson17, D Joshua18, D Vesole19, R Kyle7, R Alexanian20,
G Tricot5, M Attal21, G Merlini22, R Powles23, P Richardson24, K Shimizu25, P Tosi26, G Morgan27
SV Rajkumar7 29
1 ­ ., « », ,
; 2 ­ , , ; 3 ­ , , ; 4 ­
, , ; 5 - MIRT UAMS, , ; 6 ­
, , , 7 ­ , , ; 8 ­ ,
, ; 9 ­ , , ; 10 ­ , ;
11 ­ , , ; 12 ­ , , ; 13 ­
, ; 14 ­ , , ; 15 ­
, ; 16 ­ , , ; 17 ­
, , ; 18 ­ , , ; 19 ­
. , -, ; 20 ­
, , ; 21 ­ , , ; 22 ­ ,
, ; 23 ­ , , ; 24 ­
, , ; 25 ­ , ,
; 26 ­ , , 27 - , ,


.
/
,
. «
» «
». ,

. ,
.

.
. ,

.
INTERNATIONAL MYELOMA FOUNDATION
12650 Riverside Drive, Suite 206, North Hollywood, CA 91607-3421 USA
Tel: 818-487-7455
Fax: 818-487-7454
Email: TheIMF@myeloma.org
Website: www.myeloma.org
TRANSLATION FROM ENGLISH TO RUSSIAN PROVIDED COURTESY OF CELGENE RUSSIA.
2
: , , , ,
, .
Leukemia (2006), 1­7

,

(1, 2). ,
. ,
ECOG SWOG , ,
MRC () (3) IFM () (4). ,
/
/
(EBMT/IBMTR/ ABMTR)
, EBMT (5). ,
, .

( 1). ,
.
.

( ) (). , ,
, ,
.
, , -,
,
,
(6).

. EBMT, ()
, 5%
. , ,

3
, -
. /

.
,
, ,
. ,

. , EBMT
-, -
, ,
. , ,
«» -
.
,

(7).
()
(Freelite, Binding Site).

.
1.
__________________________________________________________________________
·


·
,


·

·
,

___________________________________________________________________________
: ­ ( ), ­ .
­ - ­ -
/ , (.
4).
4


(8) (ISS)
(9),
.
, ,
(
) 10- (, 10­14
2005 .). , ,
,
(BGD SVR) .

()
2005 ., .
, ,
2. ,
- ,
,
EBMT (Blade). ,
, ,
, ,
,
, ,
MT. ,
EBMT, .
: (1)
,
(2)
, ,




-


,
(3)
5
(),
, ,
.
2. ,
, EBMT/IBMTR
___________________________________________________________________________
·
,
( 5 6)
· ( 4)
o
6

o
, ,
/
o
« »
o


o





, -

· ( 5) ­
o
« »
o

-
( 5 6)
· ,
, ,
( « »).

()
·
( 6)
o


_________________________________________________________________________
: ­ , Abbreviations: CR, complete response; -
; EBMT ­
; ­ ; IBMTR ­
; ­ ; ­ ;
­ .

.

6
,
, (1, 8, 9).
,
. 3
.

- ­ ,
(6). , - ­
, «»,
,
, ,
- (10).
, (),
(), () (.
5 6).
(3, 11).
« » ()
, «». ,
« »
. ,

« » ()
.
, . ()

, , , , (. 5),
.
, ,
.
7
3. ,
__________________________________________________________________________
- /
/

:b
(>11.5 /) [>2.65 /]
( >2 /) [177 / ]
( <10 / 2 / ) ( <12.5
/c 1.25 / )
( )
__________________________________________________________________________
­ -
.
-
10% ;
«». /
(), ,
« » « », ,
30% / .
b ­ .
­ : 10 / 12.5 / [ 100 /].

4
. . -,
,
, -
. ,
, 1-2
(12, 13). ­ ,
6 ,
. , 6 ,
.
; ,

, ,
. , ,
, .
, , / (1).
8
,
. -, (Freelite, The Binding
Site, , ) ­
, ,
(14). ,
­ ,
(15) (Kumar S et al. Blood
2005; 106: 971a, abs 3479). ,
,
, . -,
,
, ­
10 / (<100 /). -, ­
, (16).
.
,

- / ,
-
() (17).



5. :
().
. ­
, . ,
,
,
. ,
9
,
.
4.
___________________________________________________________________________
-
-
(),
, , ,
IgA, -.
(.., IgA)
- ,

. ,
;

.
-
().
.

,
, «» ,
:
- 1 / (10 /)[10 /]
- 200 /24
: 10 / (100 /), ,
.
,
. , ,
,
, ,
.


, ­ .
« », ,

, .
10
, (
) ; ,

 .
, ,
,
, .

,
.

, ,
- .


-.
,
, .
,
.
___________________________________________________________________________
: ­ ; ­ ; ­
; ­ ; ­ ;
­ .
­
.
, IFM (4),
, .
, , 90%
; ,
, ,
. ,
(1). EBMT,

«» . ,

- .
;
, - 1 /,
­ 200 /. , , ,
11
,
.

. ,
, ,
.
6.

.
- ,
- (
). ,
()
, EBMT.

, , ,
, (
). ,

,
. ,
, , «
». «» , CRAB,
. ,
, 6. ,
, /
; ,
.
, ,
. ,
.
, .
- , -18-
12
()/- () (Walker R et
al. Blood 2004; 104: 217a, abs 758) (18,19).
5. :


a



(b),




,
5% b

-
, ,
- 90%
- 100 24

50%- -
- 90% 200
24 .
- d,
-

50%.
- ,
,
-
50%, ,
30%.
,
,
50%
(
, ,



;



)
: ­ ; ­ ; ­
; ­ ; ­ ;
­ .
­ ,
;
13
( ).
.
b ­ .
­ / k/l.
k/l, / ,
100 . ,
, - k/l = 44:1 < 1:2.
d ­ . 4.

, , ,
(Tricot G et al. Blood 2004; 104: 265a, abs 926) (6, 20­
22).
.
·
: ­
.
. ,
.
·
(). ,
«». .
, ,
, , .
,
, «»
. .
·
: ,
, , ,
.
.
·
():
.
.
·
: ,
, 5.
( )
,





,

14
, , .
, /
. ­
.
6. :








:

25% :

- / (
0.5 /)b
- / (
200 /24 )

- :

(
> 10 /)

: % 10%c






(
>11.5 /, 2.65 /),





:

/
( CRAB)b


,
,

.
15
1.

2.

. ­


50% ( 1
)
3. (>11.5 /) [2.65
/]
4. 2 /
[1.25 /] ( . 3)
5.
2 / [177 / ]
a

(
:
,
-
)d
,

5%


(,
,
, . )
: ­ ; ­
­ ,
;
b -
- 1 /, - 5 /.
­ 5%, 10% .
d ­
.


/ .
.

.
·
5 .
·
,
.
16
·

, , /
/ . ,
.

.
·
,
.
(23 ­
29). , (27),
TT-2 ,

. .
, 83%
. ,
«» «» ­ ,
. , ,
(28) / (MP)
MP- . ,
, .

(1).

,
.
,

.
,

17

.

1 Durie BGM. New approaches to treatment for multiple myeloma: durable remission and quality of life as
primary goals. Clin Lymphoma Myeloma 2005; 6: 181­190.
2 Rajkumar SV, Dispenzieri A. Evaluation and monitoring of response to therapy in multiple myeloma.
Haematologica 2005; 90: 1305­1308.
3 Child JA, Morgan G, Davies F, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with
hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875­1883.
4 Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous
stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 26: 2495­2502.
5 Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease
response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic
stem cell transplantation. Br J Haematol 1998; 102: 1115­1123.
6 Durie BGM, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does
not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. J
Clin Oncol 2004; 22: 1857­1863.
7 Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR et al. POEMS syndrome:
definitions and long-term outcome. Blood 2003; 101: 2496­2506.
8 International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple
myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;
121: 749­757.
9 Greipp PR, San Miguel J, Durie BGM, Crowley J, Barlogie B, Blade J et al. International staging system for
multiple myeloma. J Clin Oncol 2005; 23: 3412­3420.
10 Durie BGM. Staging and kinetics in multiple myeloma. In: Salmon SE (ed). Clinics in Haematology:
Myeloma and Related Disorders, Vol. 2, Number 1, WB Saunders Company, Ltd: Alden Press, Ocford, 1982,
pp 3­18.
11 Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase II study of
bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609­2617.
12 Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al. PAD combination therapy (PS-
341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J
Haematol 2005; 129: 755­762.
13 Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light chain measurements
for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900­2902.
14 Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum testing for assessment of patients
with Bence­Jones myeloma. Lancet 2003; 361: 489­491.
15 Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child A, Bradwell AR. Serum free light chains for
monitoring multiple myeloma. Br J Haematol 2004; 126: 348­354.
16 Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T et al. Doxorubicin and
dexmaethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for
multiple myeloma. Br J Hematol 2006; 132: 155.
17 Rajkumar SV, Kyle RA, Therneau TM, Melton III LJ, Bradwell AR, Clark RJ et al. Serum free light chain
ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.
Blood 2005; 106: 812­817.
18 Kyle RA, Schreiman JS, McLeod RA, Beabout JW. Computed tomography in diagnosis and management of
multiple myeloma and its variants. Arch Int Med 1985; 145: 1451­1452.
19 Durie BGM, Waxman AD, D'Angeloa A, William CM. Whole body F-FDG18 PET identifies high-risk
myeloma. J Nucl Med 2002; 43: 1457­1463.
20 Durie BGM. Is magnitude of initial response predictive for survival in multiple myeloma? Ann Oncol 1999;
2: 166­169.
21 Lahuerta JJ, Martinez-Lopez J, de la Serna J, Blade J, Grande C, Alegra A et al. Remission status defined by
immunofixation versus electrophoresis following autologus transplantation has a major impact on the outcome
of multiple myeloma patients. Br J Haematol 2000; 109: 438­446.
18
22 Riccardi A, Mora O, Tinelli C, Porta C, Danova M, Brugnatelli S et al. Response to first-line chemotherapy
and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomized
protocol. Eur J Cancer 2003; 39: 31­37.
23 Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and
dexamethasone over vincristine­ doxorubicin­dexmaethasone (VAD) as primary therapy in preparation for
autologous transplantation for multiple myeloma. Blood 2005; 106: 359.
24 Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E, Facon T et al. Bortezomib or high-dose
dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487­2498.
25 Rajkumar SV, Dispenzieri A. Evaluation and monitoring of response to therapy in multiple myeloma.
Haematologica 2005; 90: 1305­1308.
26 Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy
compared with high dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial
S9321. J Clin Oncol 2006; 24:929­936.
27 Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and
hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021­1030.
28 Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone
therapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple
myeloma: a randomized controlled trial. Lancet 2006; 367: 825­831.
29 Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission
with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037­
1043.
###

Document Outline